Interview: The Pace Quickens For Calliditas's Berger's Disease Candidate

 
• By John Davis

A Phase III trial design change could result in quicker patient access for Calliditas’s product candidate for Berger’s disease, and boost the growth potential for the Swedish biotech.    

Lucander_Renee
Calliditas CEO Renee Aguiar-Lucander • Source: Calliditas

More from Immunological

More from Therapy Areas